In a new study researchers found that people receiving Wegovy (semaglutide) lost an average of 10% of their body weight after four years. An earlier analysis of data from this trial found that semaglutide reduced the risk of heart attack, stroke and cardiovascular death in people with obesity or who are overweight.
Healthline Multiple Sclerosis
June 10, 2025
People Taking Wegovy Continue to Maintain Weight Loss 4 Years Later
 
READ ON
→
How Miss America Madison Marsh Is Working to Improve Cancer Care
 
READ ON
→
How Common Are GLP-1 Drugs Like Ozempic? 13% of U.S. Adults Have Used Them
 
READ ON
→
Navigating Health Insurance with MS
 
READ ON
→
MORE STORIES
RESOURCE FOR YOU
 
 
 
COPD CARE TEAM BUILDER
Overall health
 
Lung health
Breathing difficulties
 
Surgery for COPD
Quitting smoking
 
Diet or nutrition
HEALTHLINE RESOURCE
 
What we’re reading next
What Causes Sports Anxiety? Plus, Tips to Get Your Game (Back) On
A Guide to Foods That May Be Difficult to Digest as You Age
TSH Blood Test: What Medicare Covers
What Paperwork Do I Need to Bring to a Doctor's Appointment?
 
healthline
FB   Tiktok   TW   youtube   INSTA